medigraphic.com
SPANISH

Revista Clínica de la Escuela de Medicina de la Universidad de Costa Rica

  • Contents
  • View Archive
  • Information
    • General Information        
    • Directory
  • Publish
    • Instructions for authors        
  • medigraphic.com
    • Home
    • Journals index            
    • Register / Login
  • Mi perfil

2020, Number 4

Next >>

Rev Clin Esc Med 2020; 10 (4)

Migraine Management in the Emergency Department

Cen FYS, Jiménez TI, Chaverri PG, Marín CA, Elizondo VJR
Full text How to cite this article

Language: Spanish
References: 19
Page: 1-10
PDF size: 147.61 Kb.


Key words:

Migraine Disorders, Epidemiology, Disease Management.

ABSTRACT

Migraine is a chronic, neurovascular, episodic and multifactorial condition; it affects men and women around the world. It is caused by genetic and environmental factors. The clinical presentation consists of recurrent headache, this may or may not be pulsatile and may be associated with nausea, vomiting, photophobia or phonophobia. Neuroimaging studies are performed in the presence of headache red flags. The treatment of acute pain is determined according to the severity and frequency of the migraine attacks and the taking or not of previous medication.


REFERENCES

  1. Jes O; André B; Robert K et al. International headache society, The International Classification of Headache Disorders, 3rd edition. Headache Classification Committee of the International Headache Society (IHS). 2018; Vol 38 (Núm1): 18-28.

  2. Anjel B. Morbidity and mortality weekly, M.M.W.R, QuickStats: Percentage* of Adults Aged ≥18 Years Who Reported Having a Severe Headache or Migraine in the Past 3 Months, † by Sex and Age Group. National Health Interview Survey, § United States 2015;66(24) (Núm 1): 654.

  3. Lipton R, Bigal. M, Diamond M, Reed M, Stewart W. et al. Migraine prevalence, disease burden, and the need for preventive therapy. AAN Enterprises, Inc. January 30, 2007; NEUROLOGY 68(1): 343-349

  4. Carlos B, Maria Carla B. Migraña. Elsevier, Neurología Argentina. junio 2013; Vol 5 (Núm 2): 94,95.

  5. Jadwiga L, Glen S. Migraine prophylaxis: who, why, and how. CLEVELAND CLINIC JOURNAL OF MEDICINE. septiembre 2006;73(Núm 9): 793-814.

  6. F Michael C. Pathophysiology of Migraine. Medical Publishers, Inc. 2006; SEMINARS IN NEUROLOGY, 26 (Núm2): 171-177.

  7. Werner J. Becke, W.J.B. The Diagnosis and Management of Chronic Migraine in Primary Care. American Headache Society. Mayo 2017;57(9): 1471- 1479.

  8. Serena C, Smita P, Tim R, Martin U. Diagnosis and management of headaches in young people and adults: summary of NICE guidance. BMJ. September 2012; Guidelines.

  9. Annette D, Franz J.W, Daniel F.H, Ashley H.A, Sepideh A.H. Appropriateness Criteria Headache. American College of Radiology. 2014; Vol. (Num.): 1-9

  10. Michael.D, Devon R.M, Mark B, George A.T, Douglas C.M. Does This Patient with Headache Have a Migraine or NeedNeuroimaging? JAMA. 2006;296(10): 1274-1282

  11. Serena L.O, Benjamin W.F, Suzanne C, Mia T.M, Cynthia B. Management of Adults with Acute Migraine in the Emergency Department: The American Headache Society Evidence Assessment of Parenteral Pharmacotherapies. Wiley Periodicals, Inc. June, 2016; Vol56 (1): 911-936.

  12. Silberstein S, Todd J.S. The acute treatment of migraine in adults: the american headache society evidence assessment of migraine pharmacotherapies. Wiley Periodicals, Inc. January 2015;55 (Num): 3-20.

  13. Laurence L.B, Bruce a chabner, B.C, Björn c knollmann, B.K. Goodman & Gilman: Las Bases Farmacológicas De La Terapéutic. (13ed ed.). Ciudad de México, México: McGraw-Hill Global Education Holdings, LLC; 2018.

  14. Stephen D.S. Current management: migraine headache. ASAP/Cambridge University. 2017;17(45,26): 4-10.

  15. Michael R, Peter R, Barnet E, John R.A. ED Treatment of migraine patients has changed. American Journal of Emergency Medicine. 2015;22(1): 2-8.

  16. Tina B.M, Sydney M. Toronto Notes. (34ed ed.). Totonto, Canada; 2018.

  17. Mojtaba K, Nahid H.N, Fateme Y.A, Mohammad T, Soudeh S.G. Effectiveness of intravenous dexamethasone, metoclopramide, ketorolac, and chlorpromazine for pain relief and prevention of recurrence in the migraine headache: a prospective double-blind randomized clinical trial. Neurological Sciences, Springer. February 2019;1(1): 1-7.

  18. Kasra M, Stewart T, Jennifer S.K. Menstrual Migraine and Treatment Options: Review. Wiley Periodicals, 2016 American Headache Society; Vol.1(1): 194-204.

  19. Stephen D.S. Practice parameter: Evidence-based guidelines for migraine headache (an evidencebased review): Report of the Quality Standards Subcommittee of the American Academy of Neurology. AAN Enterprises, Inc. 2000;55(6): 754- 752.




2020     |     www.medigraphic.com

Mi perfil

C?MO CITAR (Vancouver)

Rev Clin Esc Med. 2020;10